Those who qualify may receive:
There is no obligation, so see if you may qualify now.
What to expect
The investigational vaccine will be studied alongside an approved 20-valent pneumococcal conjugate vaccine (PCV20). Pneumococcal infections can cause problems such as pneumonia and meningitis. Like RSV, pneumonia can severely affect older adults.
If you choose to take part in the study, you will be randomly assigned to either Group 1 or Group 2.